G1 Therapeutics Inc (NAS:GTHX)
$ 7.15 0 (0%) Market Cap: 377.22 Mil Enterprise Value: 364.45 Mil PE Ratio: 0 PB Ratio: 15.31 GF Score: 34/100

G1 Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 08:15PM GMT
Release Date Price: $15.93 (+1.72%)
Jason Russell;Morgan Stanley;Executive Director

Good afternoon. My name is Jason Russell. I'm member of the Morgan Stanley Healthcare Investment Banking team. And I'm excited to be here this afternoon to speak with the G1 team. We're joined by G1's CEO, Mark Velleca; as well as G1's Chief Commercial Officer, Soma Gupta.

It's an incredibly exciting time for G1 with the potential for the company's first NDA approval coming in early 2021. So I'm looking forward to today's discussion, Mark and Soma.

Maybe before I jump in, a quick disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect to reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot